APP and Alzheimer disease: In the AD murine model (APP/PS1), long-term oral administration of boldine could inhibit hemichannel activation in astrocytes, accompanied by reduced intracellular Ca2+ in astrocytes, decreased gliotransmitter release, and alleviated neuronal damage in the hippocampus (Yi et al., 2017).